Clariane Past Earnings Performance

Past criteria checks 0/6

Clariane's earnings have been declining at an average annual rate of -36.2%, while the Healthcare industry saw earnings growing at 4.4% annually. Revenues have been growing at an average rate of 7.9% per year.

Key information

-36.2%

Earnings growth rate

-39.6%

EPS growth rate

Healthcare Industry Growth	15.7%
Revenue growth rate	7.9%
Return on equity	-2.0%
Net Margin	-1.9%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Clariane makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:KO2 Revenue, expenses and earnings (EUR Millions)
Date	Revenue	Earnings	G+A Expenses
31 Dec 23	4,996	-92	545
30 Sep 23	4,865	-32	527
30 Jun 23	4,735	28	509
31 Mar 23	4,587	32	483
31 Dec 22	4,438	36	458
30 Jun 22	4,288	85	439
31 Mar 22	4,212	92	434
31 Dec 21	4,137	100	430
30 Sep 21	4,047	76	404
30 Jun 21	3,941	60	425
31 Mar 21	3,857	50	431
31 Dec 20	3,773	39	437
30 Sep 20	3,728	57	446
30 Jun 20	3,683	74	456
31 Mar 20	3,648	94	452
31 Dec 19	3,613	115	449
30 Sep 19	3,542	117	528
30 Jun 19	3,471	119	607
31 Mar 19	3,404	121	686
31 Dec 18	3,336	123	765
30 Sep 18	3,280	152	755
30 Jun 18	3,224	180	744
31 Mar 18	3,177	172	739
31 Dec 17	3,131	163	735
30 Sep 17	3,091	150	736
30 Jun 17	3,052	137	738
31 Mar 17	3,017	134	733
31 Dec 16	2,981	131	728
30 Sep 16	2,880	87	706
30 Jun 16	2,779	42	684
31 Mar 16	2,676	50	674
31 Dec 15	2,573	59	664
30 Sep 15	2,553	77	664
30 Jun 15	2,533	95	664
31 Mar 15	2,378	78	631
31 Dec 14	2,222	61	597
30 Sep 14	1,938	44	526
30 Jun 14	1,654	27	455
31 Mar 14	1,505	28	423
31 Dec 13	1,356	29	391
30 Sep 13	1,286	29	378
30 Jun 13	1,216	29	364

Quality Earnings: KO2 is currently unprofitable.

Growing Profit Margin: KO2 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: KO2 is unprofitable, and losses have increased over the past 5 years at a rate of 36.2% per year.

Accelerating Growth: Unable to compare KO2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KO2 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-7.5%).

Return on Equity

High ROE: KO2 has a negative Return on Equity (-2.04%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Clariane Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings released

Clariane SE to Report First Half, 2024 Results on Jul 30, 2024

Clariane SE to Report Fiscal Year 2023 Results on Feb 28, 2024

First half 2023 earnings released

Full year 2022 earnings released

Korian to Report First Half, 2023 Results on Jul 27, 2023

Recent updates

Clariane Confirms Rumor of Disposal of HAD/SSIAD Business in France

Full year 2023 earnings released

Elevation Healthcare Properties managed by Elevation Advisors signed an agreement to acquire Berkley Care Group Ltd from Clariane SE (ENXTPA:CLARI) for £207 million.

Investor sentiment improves as stock rises 22%

Investor sentiment deteriorates as stock falls 18%

Investor sentiment improves as stock rises 15%

Clariane SE to Report First Half, 2024 Results on Jul 30, 2024

Investor sentiment deteriorates as stock falls 23%

Investor sentiment deteriorates as stock falls 36%

Clariane SE to Report Fiscal Year 2023 Results on Feb 28, 2024

Investor sentiment deteriorates as stock falls 15%

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 16%

First half 2023 earnings released

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Upcoming dividend of €0.25 per share at 3.3% yield

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 21%

Full year 2022 earnings released

Korian (ENXTPA:KORI) acquired Grupo 5 Acción y Gestión Social, S.A. from Corpfin Capital Asesores, S.A., SGEIC and others.

Korian to Report First Half, 2023 Results on Jul 27, 2023

Investor sentiment deteriorated over the past week

First half 2022 earnings released

Korian Appoints Philippe Lévêque as Director and Chairman of the Ethics, Quality and CSR Committee

Upcoming dividend of €0.35 per share

Investor sentiment deteriorated over the past week

High number of new directors

Korian Proposes Dividend

Full year 2021 earnings: Revenues in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Icade Santé SAS completed the acquisition of 2 nursing homes in Le Teilleul and Notre-Dame-de-Sanilhac from Korian (ENXTPA:KORI) for €13 million.

Korian Provides Sales Guidance for the Year 2022

First half 2021 earnings released: EPS €0.31 (vs €0.13 in 1H 2020)

Korian (ENXTPA : KORI) acquired a 90% stake in Santa Croce s.r.l.

Korian in Exclusive Talks to Acquire Osny Psychotherapy Centre in Val d’Oise

Icade Santé SAS acquired One Post-Acute Care Facility and Two Nursing Homes from Korian (ENXTPA:KORI).

Korian (ENXTPA:KORI) completed the acquisition of ITA Mental Health from Magnum Capital Industrial Partners.

Korian Approves Dividend, Payable on July 1, 2021

Upcoming dividend of €0.30 per share

Korian Provides Revenue Guidance for the Full Year 2021 and Full Year 2022

Korian (ENXTPA:KORI) signed an agreement to acquire ITA Mental Health from Magnum Capital Industrial Partners.

Full year 2020 earnings released

Revenue beats expectations

Korian (ENXTPA:KORI) acquired unknown minority stake in Viva Son Group.

New 90-day high: €32.34

Korian Demonstrates the Relevance of its Asset Smart Strategy through a Partnership with BNP Paribas Cardif and EDF Invest

Icade SA (ENXTPA:ICAD) agreed to acquire Four Nursing Homes in France from Korian (ENXTPA:KORI) for €33.5 million.

New 90-day high: €30.78

Korian (ENXTPA:KORI) completed the acquisition of Inicea Groupe from Antin Infrastructure Partners S.A.S.

Korian Signs Development Partnership with Aedifica in the Netherlands

Korian has completed a Follow-on Equity Offering in the amount of €400.250658 million.

Korian to Report First Half, 2021 Results on Jul 29, 2021

New 90-day low: €26.58

Korian to Report Fiscal Year 2020 Results on Feb 24, 2021

Korian (ENXTPA:KORI) reached a non binding deal to acquire Inicea Groupe for €360 million.

New 90-day low: €27.38

Korian Announces Executive Changes

Korian (ENXTPA:KORI) entered into an agreement to acquire Five Facilities near Amsterdam from Ontzorgd Wonen Groep B.V.

New 90-day low - €31.54

Korian (ENXTPA:KORI) acquired Santa Marinella.

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Revenue & Expenses Breakdown
Beta